Many biologics are made of or contain glycans. Examples range from adjuvants (e.g. monophosphoryl lipid A), to drugs (e.g. miglitol) to conjugate vaccines against bacteria (e.g. <i>Haemophilus influenzae</i> type b (Hib)). Glycans can even be found on the surface of serpins (e.g. A1AT) or protein vaccine antigens (e.g. SARS-CoV-2 spike glycoprotein). Many projects surrounding glycans exist at NRC. Such projects include carbohydrate conjugate vaccines, the development of adjuvants and immunomodulators as well as the production of glycoproteins such as mAbs and vaccine antigens. During this talk, I will describe my journey within the glyco-chemistry landscape at NRC. This journey started, 7 years ago, with the synthesis of an archaeol derived adjuvant candidate, then moved to the synthesis of heptose phosphates as potential HIV latency reversal agents, to the synthesis of a pentasaccharide tip from <i>Pseudomonas aeruginosa</i> as a candidate conjugate vaccine to the analysis of glycans on the surface of the COVID spike glycoprotein.

My glyco-chemistry journey within the National Research Council of Canada

Fall 2022 abstracts, posters, and presentations will launch in mid-September.

ACS Fall 2022

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.